Skip to main content
    P

    Protagonist Therapeutics Inc (PTGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $130.95
    -3.43 (-2.55%)

    Market Cap: $8.55B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Protagonist Therapeutics Inc (PTGX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Protagonist Therapeutics (PTGX) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Protagonist Therapeutics reported EPS of $3.07, above the $2.58 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    +5.83%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.46
    Range-$0.83 - $0.65
    16 analysts
    Revenue Consensus
    $22.64M
    Range$2.65M - $88.63M
    15 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.36
    Range-$0.35 - $1.85
    4 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.03+1323.8%
    60d ago-$0.13+387.7%
    30d ago-$0.13+387.7%
    7d ago-$0.09+484.5%
    Current$0.36
    Revenue Consensus
    $58.33M
    Range$16.10M - $191.00M
    5 analysts

    Next Report

    PTGX has an expected report date of Feb 23, 2027.

    Earnings History

    Of the 39 quarters below that had an estimate, PTGX beat 20, missed 18 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $274.41M, up 5726.1% from $4.71M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.07$2.58$0.13 - $3.40+18.99%BeatN/A122 up, 2 downNov 5, 2026$274.41M
    Jun 30, 2026$2.29$2.11$0.09 - $2.79+8.53%BeatN/A10N/AAug 5, 2026$213.47M
    Mar 31, 2026$0.05-$0.65-$1.23 - -$0.25+107.69%BeatN/A72 up, 3 downMay 5, 2026$56.37M
    Dec 31, 2025-$0.69-$0.34-$0.73 - $0.09-102.76%Miss-134.8%91 up, 1 downFeb 25, 2026$7.44M
    Sep 30, 2025-$0.62-$0.64-$0.79 - -$0.57+3.13%BeatN/A91 up, 1 downNov 6, 2025$4.71M
    Jun 30, 2025-$0.55-$0.52-$0.73 - -$0.09-5.77%MissN/A93 up, 4 downAug 6, 2025$5.55M
    Mar 31, 2025-$0.19$0.11-$0.58 - $1.87-272.73%Miss-105.8%81 up, 0 downMay 6, 2025$28.32M
    Dec 31, 2024$1.98$0.25-$0.64 - $1.73+692.00%Beat+350.0%71 up, 0 downFeb 21, 2025$170.64M
    Sep 30, 2024-$0.54-$0.53-$0.71 - -$0.45-1.89%MissN/A80 up, 0 downNov 7, 2024$4.67M
    Jun 30, 2024-$0.50-$0.41-$0.81 - $0.05-21.95%MissN/A60 up, 0 downAug 6, 2024$4.17M
    Mar 31, 2024$3.26$1.60-$0.62 - $3.95+103.75%BeatN/A50 up, 0 downMay 7, 2024$254.95M
    Dec 31, 2023$0.44-$0.03-$0.66 - $0.44N/AN/AN/A50 up, 0 downFeb 27, 2024$60.00M
    Sep 30, 2023-$0.58-$0.70-$0.76 - -$0.67+17.14%BeatN/A50 up, 0 downNov 2, 2023N/A
    Jun 30, 2023-$0.68-$0.66-$0.70 - -$0.60-3.03%MissN/A60 up, 0 downAug 3, 2023N/A
    Mar 31, 2023-$0.67-$0.70-$0.91 - -$0.56+4.29%BeatN/A61 up, 0 downMay 4, 2023N/A
    Dec 31, 2022-$0.69-$0.64-$0.82 - -$0.34-7.81%MissN/A61 up, 1 downMar 15, 2023N/A
    Sep 30, 2022-$0.64-$0.85-$1.05 - -$0.76+24.71%BeatN/A50 up, 0 downNov 8, 2022N/A
    Jun 30, 2022-$0.84-$0.98-$1.05 - -$0.66+14.29%BeatN/A60 up, 0 downAug 4, 2022$859000
    Mar 31, 2022-$0.43-$0.60-$1.03 - -$0.43+28.33%BeatN/A60 up, 0 downMay 4, 2022$25.72M
    Dec 31, 2021-$0.77-$0.78-$0.97 - -$0.60+1.28%BeatN/A80 up, 0 downFeb 28, 2022$8.62M
    Sep 30, 2021-$0.70-$0.66-$0.77 - -$0.57-6.06%MissN/A7N/ANov 3, 2021$10.29M
    Jun 30, 2021-$0.69-$0.53-$0.69 - -$0.10-30.19%MissN/A7N/AAug 4, 2021$2.27M
    Mar 31, 2021-$0.54-$0.56-$0.62 - -$0.45+3.57%BeatN/A5N/AMay 4, 2021$6.19M
    Dec 31, 2020-$0.48-$0.48-$0.54 - -$0.420.00%In lineN/A5N/AMar 10, 2021$5.65M
    Sep 30, 2020-$0.21-$0.56-$0.70 - -$0.56+62.50%BeatN/A4N/ANov 4, 2020$13.11M
    Jun 30, 2020-$0.57-$0.58-$0.66 - -$0.54+1.72%BeatN/A4N/AAug 6, 2020$6.22M
    Mar 31, 2020-$0.72-$0.69-$0.77 - -$0.57-4.35%MissN/A5N/AMay 7, 2020$3.65M
    Dec 31, 2019-$0.63-$0.70-$0.86 - -$0.48+10.00%BeatN/A4N/AMar 10, 2020$2.72M
    Sep 30, 2019-$0.61-$0.73-$0.84 - -$0.51+16.44%BeatN/A5N/ANov 6, 2019$4.14M
    Jun 30, 2019-$1.18-$0.27-$0.65 - $0.28-337.04%MissN/A6N/AAug 7, 2019N/A
    Mar 31, 2019-$0.58-$0.59-$0.71 - -$0.44+1.69%BeatN/A5N/AMay 8, 2019$1.56M
    Dec 31, 2018-$0.57-$0.47-$0.67 - -$0.17-21.28%MissN/A5N/AMar 12, 2019$2.35M
    Sep 30, 2018-$0.38-$0.33-$0.69 - -$0.11-15.15%MissN/A3N/ANov 6, 2018$6.12M
    Jun 30, 2018-$0.41-$0.29-$0.51 - -$0.09-41.38%MissN/A3N/AAug 7, 2018$11.67M
    Mar 31, 2018-$0.36-$0.24-$0.39 - -$0.13-50.00%MissN/A3N/AMay 9, 2018$10.78M
    Dec 31, 2017-$0.15-$0.35-$0.42 - -$0.27+57.14%BeatN/A5N/AMar 7, 2018$11.28M
    Sep 30, 2017-$0.29-$0.61N/A+52.46%BeatN/AN/AN/ANov 6, 2017$8.78M
    Jun 30, 2017-$0.89-$0.81N/A-9.88%MissN/AN/AN/AAug 8, 2017N/A
    Mar 31, 2017-$0.84-$0.59N/A-42.37%MissN/AN/AN/AMay 10, 2017N/A
    Dec 31, 2016-$0.67-$0.52N/A-28.85%MissN/AN/AN/AMar 7, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.05, after $4.20 the year before. It was -$20.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.05-148.8%
    Dec 31, 2024$4.20N/A
    Dec 31, 2023-$1.49N/A
    Dec 31, 2022-$2.60N/A
    Dec 31, 2021-$2.70N/A
    Dec 31, 2020-$1.98N/A
    Dec 31, 2019-$3.00N/A
    Dec 31, 2018-$1.72N/A
    Dec 31, 2017-$2.17N/A
    Dec 31, 2016-$20.61N/A

    Frequently Asked Questions About PTGX

    When is Protagonist Therapeutics's next earnings date?

    Protagonist Therapeutics's next earnings report is expected for Feb 23, 2027.

    Did PTGX beat earnings estimates last quarter?

    Yes. Protagonist Therapeutics reported EPS of $3.07 for the quarter ended Sep 30, 2026, above the $2.58 estimate, a 18.99% surprise.

    What EPS do analysts expect from PTGX next quarter?

    The consensus EPS estimate for Protagonist Therapeutics for the quarter ending Dec 31, 2026 is -$0.46 from 16 analysts, with estimates from -$0.83 to $0.65.

    How often does PTGX beat earnings estimates?

    Protagonist Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +56.14%.